What Is GMP?

GMP is the abbreviation for Good Manufacturing Practice, a set of regulations and guidelines governing the manufacture of pharmaceutical products. These regulations exist to ensure that products are consistently produced and controlled to defined quality standards, minimising the risks inherent in pharmaceutical production that cannot be eliminated simply by testing the finished product. In the UK and across Europe, you’ll most commonly see this referred to as EU GMP.

EU GMP guidelines cover every aspect of production, from the raw materials used at the start of the process through to the facilities, equipment and staff involved in manufacture. GMP spans manufacturing, packaging and testing, ensuring that products are both safe and compliant with the required quality standards at every stage.

 

Who Regulates GMP?

The European Medicines Agency (EMA) provides overarching guidance for EU GMP, while individual countries’ regulatory bodies are responsible for licensing both pharmaceutical products and the facilities where they are manufactured. In the UK, that role sits with the Medicines and Healthcare products Regulatory Agency (MHRA), which inspects and licenses manufacturing sites against GMP standards and has continued to align closely with EU GMP requirements since the UK’s departure from the EU.

The MHRA specifies that GMP is the minimum standard a medicines manufacturer must meet in its production processes. Under GMP, products must:

  • Be of consistent, high quality
  • Be appropriate to their intended use
  • Meet the requirements of the Marketing Authorisation (MA) or product specification

Non-compliance isn’t a minor administrative issue. A manufacturing site that fails a GMP inspection can have its licence suspended or withdrawn, halting production and supply entirely until the deficiencies are resolved.

 

Key Elements of EU GMP

EU GMP guidance is built around several interconnected pillars, all of which need to function together for a facility to remain compliant.

Pharmaceutical Quality System (PQS): The PQS is the overarching framework that ties everything else together. It should be integrated into every stage of a product’s life cycle, giving the manufacturer enough oversight of their own process to recognise when something has gone wrong before it puts product quality or patient safety at risk. Where equipment or process failures do occur, the PQS requires a proper investigation leading to corrective and preventive actions (CAPA).

Premises: The design, layout and condition of the facility itself, including cleanroom classification, airflow, segregation of activities and materials that don’t shed particles or harbour contamination.

Equipment: All manufacturing and testing equipment must be suitable for its intended use, properly maintained, calibrated and validated, with documented evidence that it performs consistently.

Utilities: Systems such as HVAC, water for injection (WFI), compressed gases and other critical utilities that directly or indirectly contact the product or the environment around it.

Personnel: Staff training, hygiene, gowning procedures and competency, since people remain one of the most significant sources of contamination in any pharmaceutical facility.

Production: The manufacturing process itself, covering everything from raw material handling to in-process controls, batch documentation and traceability.

Monitoring: Ongoing environmental and process monitoring to demonstrate that the facility continues to perform within its validated limits, rather than assuming a one-off qualification is enough.

Quality Control (QC): Independent testing and release procedures that confirm each batch meets specification before it reaches a patient.

 

GMP and Cleanrooms: The Role of Annex 1

For manufacturers producing sterile medicinal products, GMP compliance is inseparable from cleanroom design. This relationship is governed specifically by Annex 1 of the EU GMP guidelines, which provides guidance for the manufacture of sterile products, though many of its principles around contamination control, premises design, cleanroom classification and personnel gowning are also applied to non-sterile products where microbial, particulate or endotoxin control is important.

Annex 1 underwent a complete rewrite rather than a routine update. The previous version dated back to 1996 and only received partial updates in 2003 and 2007, meaning the guidance hadn’t kept pace with over a decade of advances in sterile manufacturing technology. The revised version, published by the European Commission in August 2022, brought the guidance in line with newer technologies such as Restricted Access Barrier Systems (RABS) and isolators, alongside a much stronger emphasis on proactive contamination control.

The headline change in the 2022 revision is the requirement for a documented Contamination Control Strategy (CCS). Rather than treating contamination control as a checklist of separate requirements, Annex 1 now enumerates at least 16 specific CCS elements spanning plant design, premises, personnel, utilities and raw materials, requiring manufacturers to demonstrate a joined-up approach across facility design, equipment, environmental monitoring, personnel practices and cleaning and disinfection procedures.

Annex 1 also leans heavily into automation as a contamination control principle in its own right. Because personnel are consistently identified as a major source of contamination in cleanrooms, the guidance encourages manufacturers to rely more heavily on machines and automation to remove people from the manufacturing line wherever practical, though this shift brings its own additional requirements around documentation, validation, safety and data integrity.

 

GMP Cleanroom Grades

While ISO 14644-1 classifies cleanrooms by particle count alone, Annex 1 overlays its own grading system, Grades A through D, specifically for sterile manufacturing. These grades reflect both the maximum permitted particle counts and microbial contamination limits, and are assessed in both “at rest” and “in operation” states:

  • Grade A: The critical zone for high-risk operations such as filling and aseptic connections, typically achieved with unidirectional airflow and equivalent to ISO 5.
  • Grade B: The background environment surrounding a Grade A zone in aseptic preparation and filling, generally equivalent to ISO 5 at rest.
  • Grade C and D: Cleaner areas for less critical stages of sterile product manufacture, such as preparing solutions to be filtered, with progressively less stringent particle and microbial limits.

Getting classification right isn’t simply a case of picking the lowest ISO number available. Cleanroom classification is an essential part of the qualification activities for pharmaceutical cleanrooms, confirming that the airborne contamination control system is actually effective for the process it’s protecting, and over-specifying a grade adds unnecessary cost without improving product safety.

 

Why This Matters at the Design Stage

GMP and Annex 1 compliance can’t be retrofitted as an afterthought. Airflow patterns, room pressure cascades, material selection, personnel and material flow routes, and monitoring point locations all need to be designed in from the outset if a facility is going to pass inspection and operate reliably over its lifetime. A cleanroom that looks compliant on paper but hasn’t been engineered with GMP principles in mind is far more likely to generate costly deviations, failed inspections or, in the worst case, product recalls once it’s operational.

If you’re planning a new sterile manufacturing facility or upgrading an existing one, Angstrom Technology’s cleanroom design and build team can help you translate GMP and Annex 1 requirements into a facility that’s compliant from day one.